JUNS Stock Analysis: Buy, Sell, or Hold?
JUNS - Jupiter Neurosciences, Inc. Common Stock
$0.24
0.01 (2.12%)
▲
5d:
+2.51%
30d:
+1.35%
90d:
-37.16%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When JUNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: JUNS trading at deep discount. Market pricing in -25.7% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: JUNS trading at deep discount. Market pricing in -25.7% annual earnings decline, creating value opportunity for patient investors.
In-depth Analysis How we analyze
Valuation Analysis: JUNS is currently trading at $0.24, which is considered slightly low relative to its 30-day fair value range of $0.22 to $0.29. From a valuation perspective, the stock is trading at a discount (Forward PE: 3.9) compared to its historical average (9.6). Remarkably, the market is currently pricing in an annual earnings decline of 25.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, JUNS is in a strong downtrend. Immediate support is located at $0.22, while resistance sits at $0.29.
Market Sentiment: JUNS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $30.00 (+12611.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JUNS is in a strong downtrend. Immediate support is located at $0.22, while resistance sits at $0.29.
Market Sentiment: JUNS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $30.00 (+12611.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.22 -
$0.29
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 12611.9% below Wall St target ($30.00)
Trading Range Analysis
30-Day Trading Range
$0.22 -
$0.29
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.22
Resistance Level
$0.29
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.93
Wall Street Target
$30.00
(+12611.9%)
Valuation Discount vs History
-25.7% cheaper
PE vs Historical
3.9 vs 9.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-25.7%
(market-implied from PE analysis)
1-Year Target
$0.21
(-10%)
2-Year Target
$0.19
(-19%)
3-Year Target
$0.17
(-27%)
3-Yr Target (if PE normalizes)
(PE: 4→10)
$0.42
(+78%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 3.9 to 9.6
Stabilization Target:
$0.58
(+144.1%)
PE Expansion Potential:
+144.1%
Share & Embed Analysis
Last updated: June 24, 2026 10:04 AM ET
Data refreshes hourly during market hours. Next update: 11:04 AM
Data refreshes hourly during market hours. Next update: 11:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JUNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
|
CNTA
Centessa Pharmaceuticals… |
STRONG BUY
11 analysts |
$44 | 61 BUY |
